Rapidly progressing mesothelioma in an HIV-positive patient

Our plain-English summary of Rapidly progressing mesothelioma in an HIV-positive patient, by V. Idemyor, C.E. Cherubin (The Annals of Pharmacotherapy, 1992).

The study

• Authors: V. Idemyor, C.E. Cherubin
• Journal: The Annals of Pharmacotherapy
• Published: 1992;26(3):429
• Type of article: Case report, Letter
• Cited by: 3 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

In plain English

This was a published letter describing a single patient (a case report). The patient was a 48-year-old Black man with asthma, high blood pressure and HIV infection diagnosed in 1987. The authors wrote that he apparently had no known exposure to asbestos. In July 1990 he was admitted to Rush-Presbyterian-St. Luke's Hospital with shortness of breath and fluid around the right lung. After an open chest operation he was diagnosed with mesothelioma. Two weeks after discharge he was admitted to Mercy Hospital, having lost 18 kg over the previous six months. He was given combination chemotherapy, including doxorubicin and cisplatin, and radiation to the right chest. His breathing worsened, and he died on hospital day 19, in December 1990, slightly less than six months after his symptoms began. The authors suggested it was conceivable that the weakened immune system caused by advanced HIV infection allowed the mesothelioma to develop. They stated that one case report is not conclusive proof of a true biological link. They also said it was not certain his illness ran a different course from other reported mesothelioma cases.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: case report (letter to the editor)
• Who was studied: One 48-year-old Black man with asthma, hypertension and HIV infection diagnosed in 1987, treated at Rush-Presbyterian-St. Luke's Hospital and then Mercy Hospital, July to December 1990
• Exposure: Advanced HIV infection; the authors report the patient apparently had no known asbestos exposure
• Main results:
  • The patient had a right pleural effusion and was diagnosed with mesothelioma after an open thoracotomy
  • At admission to Mercy Hospital he weighed 73.8 kg, a loss of 18 kg over the previous six months
  • On hospital day 3 he received doxorubicin hydrochloride and cisplatin without complication
  • On day 7 a chest X-ray showed complete opacification of the right side of the chest
  • He died in December 1990, slightly less than six months after first developing shortness of breath in July 1990
• The authors' conclusion: The authors considered it conceivable that the immunocompromised state of advanced HIV infection weakened the patient's immune surveillance against cancer and led to the mesothelioma
• Limitations the authors state:
  • A single case report is not conclusive proof of a true biological association between HIV and mesothelioma
  • It is not certain that the patient's course differed from other mesothelioma cases described in the literature
  • The patient's age placed him at the beginning of the age range for this cancer

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Mesothelioma.

Related studies

• Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues — K. Mizuhashi, K. Okamoto, et al. (2024)
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection — M.R. Balestra, D. Baratti, et al. (2010)
• Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study — A. Scherpereel, T. Berghmans, et al. (2011)
• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study — M.C. Garassino, J.G. Whisenant, et al. (2020)
• Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer — G. Reid, S.C. Kao, et al. (2016)
• Loss of expression of BAP1 predicts longer survival in mesothelioma — M. Farzin, C.W. Toon, et al. (2015)

Browse return to medical research.